Skip to main content
Erschienen in: Surgery Today 10/2013

01.10.2013 | Original Article

The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors

verfasst von: Kozo Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Noriko Matsumoto

Erschienen in: Surgery Today | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Purposes

Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. The risk category is usually determined by tumor size and mitotic count, but accurate preoperative diagnosis of GIST is very difficult. The purpose of this study is to evaluate the efficacy of positron emission tomography (PET)-CT for predicting the malignant potential of gastrointestinal stromal tumors.

Methods

Ten patients with GIST who underwent a preoperative PET-CT examination were divided into two groups by risk category, and various factors were compared between the two groups. The relationships between the maximum standardized uptake value (SUVmax) and GIST parameters were examined.

Results

Patients were classified into two groups by their risk category: (low/intermediate-risk or high-risk). The SUVmax was significantly higher in the high-risk group (11.0 ± 3.04) than in the low/intermediate-risk group (2.1 ± 1.5). The Ki67 labeling index was also significantly higher in the high-risk group (8.63 ± 6.2) than in the low/intermediate-risk group (1.75 ± 0.52). There was a significant correlation between the Ki67 labeling index and the SUVmax (p = 0.028) and between the mitotic index and the SUVmax (p = 0.029).

Conclusions

PET-CT can predict malignant potential. Cases with a SUVmax of over 5 may have malignant potential.
Literatur
1.
Zurück zum Zitat Kamiyama Y, Aihara R, Nakabayashi T. F-Fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg. 2005;29:1429–35.PubMedCrossRef Kamiyama Y, Aihara R, Nakabayashi T. F-Fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg. 2005;29:1429–35.PubMedCrossRef
2.
Zurück zum Zitat Eliseberg B, Jonathanharris MS. Phase II trial of neoadjuvant/adjuvant imatinib metastatic/recurrent operable gastrointestinal stromal tumor (GIST). J Surg Oncol. 2009;99:42–7.CrossRef Eliseberg B, Jonathanharris MS. Phase II trial of neoadjuvant/adjuvant imatinib metastatic/recurrent operable gastrointestinal stromal tumor (GIST). J Surg Oncol. 2009;99:42–7.CrossRef
3.
Zurück zum Zitat John O, Montemurro M, Victoria M. Early prediction of response to sunitinib after imatinib failure by F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2008;27:439–45.CrossRef John O, Montemurro M, Victoria M. Early prediction of response to sunitinib after imatinib failure by F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2008;27:439–45.CrossRef
4.
Zurück zum Zitat Haesun C, Chuslip C, Silvan C. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.CrossRef Haesun C, Chuslip C, Silvan C. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.CrossRef
5.
Zurück zum Zitat Clay H, Holdsworth D, Badawi B. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR. 2007;189:324–30.CrossRef Clay H, Holdsworth D, Badawi B. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR. 2007;189:324–30.CrossRef
6.
Zurück zum Zitat Patrick V, Valerie T, Klaus S. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. Abdom Imaging. 2009;11:23–6. Patrick V, Valerie T, Klaus S. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. Abdom Imaging. 2009;11:23–6.
7.
Zurück zum Zitat Isis G, Thuan V, Revathy I. The role of F-FDG PET in staging and early prediction ob response to therapy ob recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21. Isis G, Thuan V, Revathy I. The role of F-FDG PET in staging and early prediction ob response to therapy ob recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21.
8.
Zurück zum Zitat Ronald P, DeMatteo J, Lisa S. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608–15.CrossRef Ronald P, DeMatteo J, Lisa S. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608–15.CrossRef
9.
Zurück zum Zitat Ando K, Sugiyama M, Zhao Y, Kojima A, Yamamoto H, Yamashita Y, et al. Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate. Surg Today. 2011;41:1290–3.PubMedCrossRef Ando K, Sugiyama M, Zhao Y, Kojima A, Yamamoto H, Yamashita Y, et al. Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate. Surg Today. 2011;41:1290–3.PubMedCrossRef
10.
Zurück zum Zitat DeMatte RP, Maki RG, Samuel S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Aun Surg. 2007;245:347–52.CrossRef DeMatte RP, Maki RG, Samuel S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Aun Surg. 2007;245:347–52.CrossRef
11.
Zurück zum Zitat Wong NA, Young R, Malcomson RDG, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118–26.PubMedCrossRef Wong NA, Young R, Malcomson RDG, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118–26.PubMedCrossRef
12.
Zurück zum Zitat Charles D, Cathryn R, Demetri DG, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase. J Clin Oncol. 2008;26:626–32.CrossRef Charles D, Cathryn R, Demetri DG, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase. J Clin Oncol. 2008;26:626–32.CrossRef
13.
Zurück zum Zitat Eisenberg BL, Jonathan H, Charles B. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST)-early results of RTOG 0132. J Surg Oncol. 2009;1:42–7.CrossRef Eisenberg BL, Jonathan H, Charles B. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST)-early results of RTOG 0132. J Surg Oncol. 2009;1:42–7.CrossRef
14.
Zurück zum Zitat Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized Phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.PubMedCrossRef Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized Phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.PubMedCrossRef
15.
Zurück zum Zitat Fujimoto Y, Nakanishi Y, Yoshimura K. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39–48.PubMedCrossRef Fujimoto Y, Nakanishi Y, Yoshimura K. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39–48.PubMedCrossRef
16.
Zurück zum Zitat Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002;33:459–65.CrossRef Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002;33:459–65.CrossRef
17.
Zurück zum Zitat Otsuka H, Terazawa K, Morita M. Is FDG-PET/CT useful for managing malignant pleural mesothelioma? J Med Invest. 2009;56:16–20.PubMedCrossRef Otsuka H, Terazawa K, Morita M. Is FDG-PET/CT useful for managing malignant pleural mesothelioma? J Med Invest. 2009;56:16–20.PubMedCrossRef
18.
Zurück zum Zitat Otsuka H, Morita N, Yamashita K. FDG-PET/CT findings of autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis. Ann Nucl Med. 2007;21:593–6.PubMedCrossRef Otsuka H, Morita N, Yamashita K. FDG-PET/CT findings of autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis. Ann Nucl Med. 2007;21:593–6.PubMedCrossRef
19.
Zurück zum Zitat Otsuka H, Morita N, Yamashita K. FDG-PET/CT for cancer management. J Med Invest. 2007;54:195–9.PubMedCrossRef Otsuka H, Morita N, Yamashita K. FDG-PET/CT for cancer management. J Med Invest. 2007;54:195–9.PubMedCrossRef
20.
Zurück zum Zitat Wong R, Young R, Malcomson D. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118–26.PubMedCrossRef Wong R, Young R, Malcomson D. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118–26.PubMedCrossRef
21.
Zurück zum Zitat Burkill GJ, Badran M, Al-Muderis O. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003;226:527–32.PubMedCrossRef Burkill GJ, Badran M, Al-Muderis O. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003;226:527–32.PubMedCrossRef
22.
Zurück zum Zitat Nishida T, Kumano S, Sugiura T. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR. 2003;180:185–9.PubMedCrossRef Nishida T, Kumano S, Sugiura T. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR. 2003;180:185–9.PubMedCrossRef
23.
Zurück zum Zitat Demetri G. Identification and treatment of chemoresistant inoperable or meta-static GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571). Eur J Cancer. 2002;38:52–9.CrossRef Demetri G. Identification and treatment of chemoresistant inoperable or meta-static GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571). Eur J Cancer. 2002;38:52–9.CrossRef
24.
Zurück zum Zitat Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.PubMedCrossRef Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.PubMedCrossRef
25.
Zurück zum Zitat Valk PE. Pounds by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573–81.PubMedCrossRef Valk PE. Pounds by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573–81.PubMedCrossRef
26.
Zurück zum Zitat Vitola JV, Delbeke D, Sandler MP. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–6.PubMedCrossRef Vitola JV, Delbeke D, Sandler MP. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–6.PubMedCrossRef
27.
Zurück zum Zitat Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270–4.PubMedCrossRef Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270–4.PubMedCrossRef
28.
Zurück zum Zitat Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST. J Gastric Cancer. 2011;11:173–9.PubMedCrossRef Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST. J Gastric Cancer. 2011;11:173–9.PubMedCrossRef
Metadaten
Titel
The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors
verfasst von
Kozo Yoshikawa
Mitsuo Shimada
Nobuhiro Kurita
Hirohiko Sato
Takashi Iwata
Shinya Morimoto
Tomohiko Miyatani
Hideya Kashihara
Chie Takasu
Noriko Matsumoto
Publikationsdatum
01.10.2013
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 10/2013
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0411-6

Weitere Artikel der Ausgabe 10/2013

Surgery Today 10/2013 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.